NCT05059522 2026-04-14
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
Phase 3 Active not recruiting
Clinical Trials
33 trialsNCT06459180 2026-04-13
TroFuse-020
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07418749 2026-04-06
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04697628 2026-02-24
innovaTV 301
Seagen Inc.
Phase 3 Completed
NCT03875144 2026-02-09
MESOTIP
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Suspended
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT04956640 2025-09-25
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Phase 1/2 Recruiting
NCT04680988 2025-08-05
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02922764 2025-03-26
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Inspirna, Inc.
Phase 1 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT06758557 2025-01-23
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
Huabo Biopharm Co., Ltd.
Phase 1/2 Recruiting
NCT01001910 2024-02-28
Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Albert Einstein College of Medicine
Phase 2 Completed
NCT04943627 2022-10-05
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
Phase 3 Withdrawn
NCT03023319 2022-06-14
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Augusta University
Phase 1 Completed
NCT00230542 2018-08-13
Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00096187 2018-04-12
Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy
GOG Foundation
Phase 2 Terminated
NCT00691301 2018-01-09
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
GOG Foundation
Phase 2 Completed
NCT00702299 2016-01-01
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
University of Arizona
Phase 1 Completed
NCT01172028 2015-12-03
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
University of Arizona
Phase 1 Completed
NCT00868192 2014-10-20
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Washington University School of Medicine
Phase 2 Completed
NCT00087087 2014-02-14
Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00087100 2014-02-14
Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT00087113 2014-02-14
Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix
GOG Foundation
Phase 2 Completed
NCT00489359 2011-06-16
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT00461786 2009-12-04
A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00190983 2009-11-20
A Trial for Patients With Advanced/Recurrent Cervical Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00377520 2009-11-20
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00315861 2009-01-23
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00190918 2007-08-09
A Trial for Patients With Gestational Trophoblastic Disease
Eli Lilly and Company
Phase 2 Completed
NCT00109096 2007-05-17
Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy
Eli Lilly and Company
Phase 2 Completed
NCT00055432 2006-09-15
Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer
Eli Lilly and Company
Phase 2 Terminated